Centocor, Inc.
14 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 4 name spellings.
5
Ending by 2030
Jan 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
No maintenance fee falls due on this company's record before Nov 21, 2027.
Recent changes
- 1 term has ended since Aug 23, 2026
- Oct 2 US 7,736,650 Anti-IL-12 antibody based vectors, host cells, and methods of production and uses · term ended
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 5 of 5
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,361,474 | Anti-IL-12 antibody based vectors, host cells, and methods of production and uses In force · USPTO record | In force | USPTO record | |
| US 7,498,150 | Materials and methods to increase peptide chain expression In force · USPTO record | In force | USPTO record | |
| US 7,833,531 | Method for treating insulin sensitivity by long-acting GLP-1 receptor mimetibody agonists In force · USPTO record | In force | USPTO record | |
| US 8,093,068 | Methods for use in human-adapting monoclonal antibodies In force · USPTO record | In force | USPTO record | |
| US 7,982,007 | Cynomolgus toll-like receptor 3 In force · USPTO record | In force | USPTO record |
Also on record, not counted in the 5: 14 patents in force now held by others · 37 lapsed for an unpaid fee · 138 ended at full term · 2 surrendered on reissue. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
8 abandoned · 12 no status recorded
Showing 1 to 10 of 20, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.
| Application | Title | Filed | Status |
|---|---|---|---|
| 12/885,406 | Methods of Treating Ankylosing Spondylitis Using Anti-TNF Antibodies and Peptides of Human Tumor Necrosis Factor | Sep 17, 2010 | Abandoned |
| 12/530,546 | Mar 28, 2008 | No status recorded | |
| 12/305,034 | Jul 18, 2007 | No status recorded | |
| 12/295,318 | Mar 30, 2007 | No status recorded | |
| 11/401,391 | Methods of treating seronegative arthropathy with anti-TNF antibodies | Apr 10, 2006 | Abandoned |
| 11/182,033 | Anti-TNF antibodies and peptides of human tumor necrosis factor | Jul 14, 2005 | Abandoned |
| 11/053,750 | Methods of treating psoriasis using anti-TNF receptor fusion proteins | Feb 7, 2005 | Abandoned |
| 11/053,749 | Methods of treating rheumatoid arthritis using anti-TNF receptor fusion proteins | Feb 7, 2005 | Abandoned |
| 11/010,954 | Methods of treating ankylosing spondylitis using anti-TNF antibodies and peptides of human tumor necrosis factor | Dec 13, 2004 | Abandoned |
| 10/957,549 | Sep 30, 2004 | No status recorded |
10 of 20 applications shown.
Pro members see all 20 published applications.